NFKBIZ siRNA

NFKBIZ siRNA is a small interfering RNA (siRNA) therapeutic designed to specifically silence the **NFKBIZ gene**, which encodes IκBζ, an atypical inhibitor of NF-κB. IκBζ is a key regulator of proinflammatory cytokine expression, playing a central role in inflammatory and autoimmune diseases such as psoriasis. By locally applying NFKBIZ siRNA, typically using advanced delivery systems like ionic liquid formulations, the therapy prevents NFKBIZ mRNA translation, resulting in reduced levels of inflammatory cytokines (including TNF-α, IL-17A, IL-23, and IL-36). The primary therapeutic approach studied is topical administration for the treatment of psoriasis, where local gene silencing significantly ameliorates disease pathology without systemic side effects. Preclinical studies have demonstrated reduced erythema, scaling, epidermal thickening, and keratinocyte proliferation in treated skin[1][3][6][7].

Other names

NFKBIZ small interfering RNANFKBIZ-targeted siRNAIκBζ siRNA